期刊文献+

特纳综合征患者血清转化生长因子β的变化 被引量:2

Perturbation of the transforming growth factor β system in Turner syndrome
下载PDF
导出
摘要 目的:观察转化生长因子β(transforming growth factor-beta,TGFβ)在特纳综合征(Turner syndrome,TS)患者血清中的变化及其与内分泌和心血管参数的关系。方法:选择TS患者和健康志愿者妇女(对照组)各40例,采用酶联免疫方法测定血清中的TGFβ1、TGFβ2及转化生长因子受体(endoglin)。所有TS患者均行心血管系统磁共振和超声检查。结果:TS患者血清中TGFβ1和endoglin水平均高于对照组(P<0.000 1),而TGFβ2的水平则低于对照组(P<0.000 1)。TGFβ的改变与年龄、血压、血小板、甲状腺功能、体重指数或心血管疾病的分型无关。结论:TS患者血清中TGFβ显著性改变对疾病的研究具有重要意义。 Objective: To measure components of the circulating transforming growth factor β(TGFβ) system in patients with Turner syndrome(TS) compared to relevant controls and to ascertain correlation with endocrine and cardiovascular parameters.Methods: TGFβ1,TGFβ2 and endoglin(a vascular TGF receptor component) were measured using enzyme-linked immunoassays in the sera of 40 subjects with TS and 40 healthy volunteer women.The cardiovascular phenotype in TS subjects was extensively characterized by cardiac magnetic resonance(MR) and echo.Results: TGFβ1 levels were about 3-fold higher in TS while TGFβ2 levels were about 3.5-fold higher in controls(P 0.000 1 for both).Soluble endoglin levels were 25% higher in TS(P 0.000 1).Variation in TGFβ system components was not explained by age,blood pressure,platelet count,thyroid function,body proportions or cardiovascular phenotype.Conclusion: There is profound perturbation of the TGFβ system evident in the circulation of individuals with TS.
出处 《北京大学学报(医学版)》 CAS CSCD 北大核心 2012年第5期720-724,共5页 Journal of Peking University:Health Sciences
基金 Supported by National Institute of Child Health and Human Development
关键词 特纳综合征 转化生长因子Β 心血管疾病 X染色体 主动脉 Turner syndrome Transforming growth factor beta Cardiovascular diseases X chromosome Aorta
  • 相关文献

参考文献25

  • 1Stochholm K, Juul S, Juel K, et al. Prevalence, incidence, diag- nostic delay, and mortality in Turner syndrome [J]. J Clin Endo- crinol Metab, 2006, 91 (10) : 3897 -3902.
  • 2Lin AE, Lippe BM, Geffner ME, et al. Aortic dilation, dissec- tion, and rupture in patients with Turner syndrome[J]. J Pediatr, 1986, 109(5): 820-826.
  • 3Gravholt C, Landin-Wilhelmsen K, Stochholm K, et al. Clinical and epidemiological description of aortic dissection in Turner' s syndrome[J]. Cardiol Young, 2006, 16(5) : 430 -436.
  • 4Gravholt CH, Juul S, Naeraa RW, et al. Morbidity in Turner syn- drome [J]. J Clin Epidemiol, 1998, 51(2) : 147 -158.
  • 5Matura L, Ho V, Rosing D, et al. Aortic dilatation and dissection in Turner syndrome [J]. Circulation, 2007, 116(15) : 1663 - 1670.
  • 6Carlson M, Silberbach M. Dissection of the aorta in Turner syn- drome: Two new cases and review of 85 cases in the literature [J]. J Med Genet, 2007, 44(12) : 745 -749.
  • 7Bondy CA. Aortic dissection in Turner syndrome [ J]. Curr Opin Cardiol, 2008, 23(6): 519-526.
  • 8Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 anta- gonist, prevents aortic aneurysm in a mouse model of Marfan syn- drome [J]. Science, 2006, 312(5770): 117-121.
  • 9Jones J, Spinale F, Ikonomidis J. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis [J]. J Vasc Res, 2009, 46(2): 119 -137.
  • 10Gomez D, Zen AAH, Barges LF, et al. Syndromic and non-syn- dromic aneurysms of the human ascending aorta share activation of the Smad2 pathway [J]. J Pathol, 2009, 218(1) : 131 -142.

同被引文献10

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部